Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof

Abstract

Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.

Description

RELATED APPLICATIONS [0001] The present application is a Continuation of PCT Application No. PCT / IL2005 / 000481, filed on May 5, 2005, which claims priority from U.S. Provisional Application No. 60 / 567,824, filed on May 5, 2004 and from U.S. Provisional Patent Application No. 60 / 651,619, filed on Feb. 11, 2005. The contents of each of the above applications are incorporated herein by reference.FIELD AND BACKGROUND OF THE INVENTION [0002] The present invention relates to novel, non-tolerance inducing, NO-donating compounds and their use in the treatment of various disorders and diseases such as, for example, cardiovascular diseases, inflammation, tumor suppression and psychiatric and neurological diseases. [0003] Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular and neurological systems. [0004] Biological NO is synthesized by the enzyme nitric oxide synthase (NOS) that generates NO from L-arginine. This enzyme exists in three diff...

AI Technical Summary

Benefits of technology

The new compounds exhibit prolonged efficacy without inducing tolerance, offering improved therapeutic bioavailability and reduced side effects, making them suitable for long-term management of conditions like ischemic heart disease and hypertension.

Problems solved by technology

Whatever its biochemical basis, NO insufficiency limits NO-mediated signal transduction of normal or protective physiological processes.

However, although this administration route is used in cases where improved patient oxygenation is required, as, for example, in pulmonary hypertension (high blood pressure in the lungs) and in patients with sickle cell anemia, such direct administration of the NO active form may not reach the target organ and / or biological system, and is oftentimes associated with both biochemical and medical complications, including, for example, methemoglobinemia and direct pulmonary injury.

However, while the beneficial effects of administering NO-donors have been widely recognized, treatment with conventional nitrate preparations, as those described hereinabove, is typically limited by their therapeutic bioavailability half-life, lack of selectivity, systemic absorption accompanied by potentially adverse hemodynamic effects, and drug tolerance, with the latter being with the presently most limiting feature associated with administration of NO-donors [Ignarro L J. et al., J Cardiovasc Pharmacol.

The inadequacies in current NO-donor prodrugs have limited their use to only short-term management of angina pectoris and acute heart failure.

While the extent to which ALDH-2 contributes to GTN tolerance (impaired relaxation to GTN) and cross-tolerance (e.g., impaired endothelium-dependent relaxation) in vivo remains to be elucidated, these studies clearly indicate that the present use of organic nitrates as NO-donors is highly limited.

Images